Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study

被引:1
作者
Suen, Matthew [1 ]
Manski-Nankervis, Jo -Anne [1 ]
McBride, Caroline [1 ]
Lumsden, Natalie [1 ]
Hunter, Barbara [1 ]
机构
[1] Univ Melbourne, Dept Gen Practice & Primary Care, Level 3,North Wing,Bldg,181 Grattan St,Med Bldg, Parkville 3010, Australia
关键词
type; 2; diabetes; CP-FIT; electronic health; clinical decision support tool; primary care; SGLT2; inhibitor; complication; tool; digital health intervention; thematic analysis; decision support; diabetes management; CLINICAL DECISION-SUPPORT; PRIMARY-CARE; MANAGEMENT;
D O I
10.2196/50737
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Tune 2 Diabetes
    Choi, Jin Bong
    Yoo, Je Mo
    Lee, Ye-Jee
    Kim, Jae Woong
    Lee, Seung-Ju
    Kim, Hee Youn
    Lee, Dong Sup
    Ko, Seung-Hyun
    Choe, Hyun-Sop
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2020, 24 (01) : 21 - 28
  • [42] Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Stabel, Lena
    Kannenkeril, Dennis
    Ott, Christian
    Bramlage, Peter
    Schiffer, Mario
    Achenbach, Stephan
    Schmieder, Roland E.
    ESC HEART FAILURE, 2021, 8 (06): : 5327 - 5337
  • [43] Sodium-glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis
    Mishra, Rahul
    Elshimy, Ghada
    Kannan, Lakshmi
    Raj, Rishi
    BMJ CASE REPORTS, 2022, 15 (07)
  • [44] Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor
    Zhang, Lydia
    Tamilia, Michael
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (25) : E766 - E768
  • [45] Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
    Maigret, Lucie
    Basle, Lucile
    Chatelet, Valerie
    Ecotiere, Laure
    Perrin, Peggy
    Golbin, Leonard
    Bertrand, Dominique
    Anglicheau, Dany
    Poulain, Coralie
    Garrouste, Cyril
    Danthu, Clement
    Boud'hors, Charlotte
    Le Meur, Yannick
    Dekeyser, Manon
    Duthe, Fabien
    Sautenet, Benedicte
    Deliege, Pierre-Guillaume
    Gatault, Philippe
    KIDNEY INTERNATIONAL REPORTS, 2025, 10 (03): : 816 - 827
  • [46] A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
    Ikeda, S.
    Takano, Y.
    Cynshi, O.
    Tanaka, R.
    Christ, A. D.
    Boerlin, V.
    Beyer, U.
    Beck, A.
    Ciorciaro, C.
    Meyer, M.
    Kadowaki, T.
    DIABETES OBESITY & METABOLISM, 2015, 17 (10) : 984 - 993
  • [47] Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema
    Oyakawa, Takuya
    Miura, Keita
    Muraoka, Nao
    Iida, Kei
    Fujita, Ayano
    Naito, Tateaki
    Takahashi, Toshiaki
    THORACIC CANCER, 2025, 16 (02)
  • [48] Solution is not simple; sodium-glucose cotransporter-2 inhibitor use in Conn syndrome
    Soyaltin, Utku
    BLOOD PRESSURE MONITORING, 2024, 29 (04) : 195 - 197
  • [49] The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
    Lan, Nick S. R.
    Fegan, P. Gerry
    Yeap, Bu B.
    Dwivedi, Girish
    ESC HEART FAILURE, 2019, 6 (05): : 927 - 935
  • [50] Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
    Nunoi, Kiyohide
    Sato, Yuichi
    Kaku, Kohei
    Yoshida, Akihiro
    Suganami, Hideki
    DIABETES OBESITY & METABOLISM, 2019, 21 (07) : 1715 - 1724